昌发展投资企业诺诚健华、数坤科技、吉因加取得重大进展

网络
19 Nov 2020

近日,昌发展投资企业在多个方面取得重大突破。诺诚健华旗下创新药奥布替尼获美国FDA批准开展治疗多发性硬化症临床II期研究;母基金间接投资企业数坤科技获批全球首张心脏冠脉狭窄AI医疗器械注册证、吉因加与中国胸部肿瘤研究协作组共同设立的CTONG-吉因加联合实验室正式启动,满分通过NCCL、CAP多项室间质评和能力验证,并于近日获得2.5亿元B+轮融资。昌发展与合作基金联合投资企业诺诚健华今年3月于...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10